Market Access

Market Access - Axcellant

Market Access

  1. Feb 28, 2025

What Does the ‘Market Access’ Mean?

Market access refers to the process of ensuring that new pharmaceutical products or medical devices are available and accessible to patients in a given healthcare system. It involves navigating complex regulatory, pricing, and reimbursement landscapes to bring innovative treatments to market successfully.

The term encompasses strategies and activities aimed at demonstrating the value of a product to various stakeholders, including payers, healthcare providers, and policy makers. Market access teams work to overcome barriers to entry, negotiate pricing and reimbursement terms, and develop evidence to support the adoption of new therapies in clinical practice.

Why Is the ‘Market Access’ Important in Clinical Research?

Market access considerations are crucial in clinical research as they inform study design and endpoint selection. By aligning clinical trials with market access requirements, researchers can generate evidence that supports regulatory approval, pricing negotiations, and reimbursement decisions.

Understanding market access challenges early in the development process helps optimize resource allocation and increases the likelihood of commercial success. It ensures that clinical research efforts are strategically focused on addressing the needs of patients, healthcare systems, and payers, ultimately facilitating the transition from successful trials to widespread treatment availability.

Good Practices and Procedures

  1. Conduct early health technology assessments to identify value drivers and potential hurdles in target markets
  2. Develop robust health economic models to demonstrate cost-effectiveness across different healthcare systems
  3. Engage in scientific advice meetings with regulatory bodies and payers to align on evidence requirements
  4. Implement patient-reported outcome measures in clinical trials to capture real-world value beyond clinical endpoints
  5. Create tailored value dossiers for each key market, addressing specific local healthcare priorities and decision-making criteria

Related Terms

Resources

Large Language Models in Nuclear Cardiology: From Experimental Tools to Clinical Infrastructure

3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…

From Half-Life to Clinical Impact: Mastering Time-Critical Supply Chains

How Axcellant helped a diagnostic study overcome isotope supply, manufacturing, and logistics constraints In radiopharmaceutical development, we often say that…

How ACT EU Is Forcing a Global Approach to Trial Timelines

Europe’s clinical trials market is entering a more practical phase in its approach to competitiveness. With the Clinical Trials Regulation…